The cell line is available as live cells approximately 3–4 million cells per sample in a T25 Flask.

**Potential Commercial Applications:**
- A tool to further understand fibrosis
- A tool to study granule formation, early mast cell development, degranulation and chemotaxis
- Screening tool to identify target compounds for the treatment of pulmonary fibrosis

**Competitive Advantages:**
- First progenitor mast cell line known to produce fibrotic elements
- Progenitor mast cell line with rapid growth, no cytokine stimulation needed. Cell doubling time of 2–3 days

**Inventors:** Arnold S. Kirchenbaum and Dean D. Metcalfe, both of NIAID.

**Publications:**
Kirchenbaum AS et al. Immunophenotypic and Ultrastructural Analysis of Mast Cells in Hermansky-Pudlak Syndrome Type-1: A Possible Connection to Pulmonary Fibrosis.; PLoS One. 2016, Jul 26;11(7):e0159177, PMID 27459687

**Intelectual Property:**

**Collaborative Research Opportunity:**  
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this invention.

For collaboration opportunities, please contact Dr. Dianca Finch; 240–669–5092, dianca.finch@nih.gov.

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Government-Owned Invention; Availability for Licensing**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**FOR FURTHER INFORMATION CONTACT:**
Licensing information may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished scientific data.

**SUPPLEMENTARY INFORMATION:**

Technology description follows.

A Human Progenitor Mast Cell Line for Allergic and Fibrotic Research and Therapeutic Screening

**Description of Technology:**
Hermansky-Pudlak Syndrome type-1 (HPS-1) is a rare genetic disorder that affects around 1 in 500,000 people worldwide and 1 in 1,800 Puerto Ricans. Patients with HPS-1 display oculocutaneous albinism, bleeding due to platelet abnormality, and pulmonary fibrosis. Those that develop pulmonary fibrosis often succumb and live no more than a decade after early onset of breathing problems.

Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) have developed the HPS-1 proMastocyte (HPM) cell line, containing an HPS-1 mutation. This cell line resembles a progenitor mast cell with reduced granule formation, significant chemotactic ability, and is the first mast cell line shown to constitutively release cytokines, chemokines, and most importantly fibrotic proteins. This cell line serves as a model to study granule formation, early mast cell development, chemotaxis and mechanisms controlling synthesis of molecules contributing to fibrosis.
Agenda: To review and evaluate grant applications.
Place: Renaissance Mayflower Hotel, 1127 Connecticut Avenue NW., Washington, DC 20036.
Contact Person: Marita R. Hopmann, Ph.D., Scientific Review Officer, Division of Scientific Review, National Institute of Child Health and Human Development, 6710B Bethesda Drive, Bethesda, MD 20892, (301) 435–6911, hopmannm@mail.nih.gov.
Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel, Comparative and Developmental Perspectives on the Emergence of Cognitive Competence.
Date: December 7, 2016.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6710B Rockledge Drive, Bethesda, MD 20718 (Telephone Conference Call).
Contact Person: Marita R. Hopmann, Ph.D., Scientific Review Officer, Division of Scientific Review, National Institute of Child Health and Human Development, 6710B Bethesda Drive, Bethesda, MD 20892, (301) 435–6911, hopmannm@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: October 26, 2016.
Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016–26261 Filed 10–31–16; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HOMELAND SECURITY
U.S. Customs and Border Protection

Accreditation and Approval of Intertek USA, Inc., as a Commercial Gauger and Laboratory

AGENCY: U.S. Customs and Border Protection

ACTION: Notice of accreditation and approval of Intertek USA, Inc., as a commercial gauger and laboratory.

SUMMARY: Notice is hereby given, pursuant to CBP regulations, that Intertek USA, Inc., has been approved to gauge and accredited to test petroleum and petroleum products for customs purposes for the next three years as of July 14, 2015.

DATES: Effective Dates: The accreditation and approval of Intertek USA, Inc., as commercial gauger and laboratory became effective on July 14, 2015. The next triennial inspection date will be scheduled for July 2018.


SUPPLEMENTARY INFORMATION: Notice is hereby given pursuant to 19 CFR 151.12 and 19 CFR 151.13, that Intertek USA, Inc., 230 Crescent Ave, Chelsea, MA 02150, has been approved to gauge and accredited to test petroleum and petroleum products for customs purposes, in accordance with the provisions of 19 CFR 151.12 and 19 CFR 151.13. Intertek USA, Inc., is approved for the following gauging procedures for petroleum and certain petroleum products set forth by the American Petroleum Institute (API):

<table>
<thead>
<tr>
<th>API chapters</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Tank gauging.</td>
</tr>
<tr>
<td>7</td>
<td>Temperature Determination.</td>
</tr>
<tr>
<td>8</td>
<td>Sampling.</td>
</tr>
<tr>
<td>12</td>
<td>Calculations.</td>
</tr>
<tr>
<td>17</td>
<td>Maritime Measurements.</td>
</tr>
</tbody>
</table>

Intertek USA, Inc., is accredited for the following laboratory analysis procedures and methods for petroleum and certain petroleum products set forth by the U.S. Customs and Border Protection Laboratory Methods (CBPL) and American Society for Testing and Materials (ASTM):

<table>
<thead>
<tr>
<th>CBPL No.</th>
<th>ASTM</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>27–50</td>
<td>D93</td>
<td>Standard Test Methods For Flash-Point by Pensky-Martens Closed Cup Tester.</td>
</tr>
<tr>
<td>27–58</td>
<td>D5191</td>
<td>Standard Test Method For Vapor Pressure of Petroleum Products.</td>
</tr>
<tr>
<td>N/A</td>
<td>D1319</td>
<td>Standard Test Method for Hydrocarbon Types in Liquid Petroleum Products by Fluorescent Indicator Absorption.</td>
</tr>
<tr>
<td>N/A</td>
<td>D3606</td>
<td>Standard Test Method for Determination of Benzene and Toluene in Finished Motor and Aviation Gasoline by Gas Chromatography.</td>
</tr>
<tr>
<td>N/A</td>
<td>D4815</td>
<td>Standard Test Method for Determination of MTBE, ETBE, TAME, DIPE, tertiary-Amyl Alcohol and C1 to C4 Alcohols in Gasoline by Gas Chromatography.</td>
</tr>
</tbody>
</table>

Anyone wishing to employ this entity to conduct laboratory analyses and gauger services should request and receive written assurances from the entity that it is accredited or approved by the U.S. Customs and Border Protection.